ArticlemSphere2021
Deciphering Multidrug-Resistant Acinetobacter baumannii from a Pediatric Cancer Hospital in Egypt.
Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prevalence of colistin-resistant Enterobacteriaceae isolated from clinical samples in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Review
- Comparative clinical outcomes of pandrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae infections in children.BMC infectious diseases · 2026Article
- Convergent evolution of ST2 and ST164 mediates dissemination of the blaAnnals of clinical microbiology and antimicrobials · 2026Article
- Analysis of clinical characteristics and whole-genome sequencing of carbapenem-resistant Acinetobacter baumannii isolates from pediatric patients in Guangxi, China.BMC microbiology · 2026Article
- Colistin-resistance amongJAC-antimicrobial resistance · 2026Review
- Limits of rapid diagnostics: genomic and structural insights into OXA-48-like mediated carbapenem resistance inFrontiers in microbiology · 2026Article
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Next-Generation Sequencing for Infectious Disease Diagnostics in Pediatric Patients with Malignancies or After Hematopoietic Cell Transplantation: A Systematic Review.Journal of clinical medicine · 2025Review
- Clinical Analysis ofJournal of clinical medicine · 2025Article
- Comparative genomics of Acinetobacter baumannii from Egyptian healthcare settings reveals high-risk clones and resistance gene mobilization.BMC infectious diseases · 2025Article
- Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii.npj antimicrobials and resistance · 2025Article
- Microbiological Profiles and Resistance Patterns in Pediatrics With Cancer: An 8-Year Study at a Comprehensive Cancer Center in Jordan.Cancer reports (Hoboken, N.J.) · 2025Article
- Genomic characterization and identification of multiple drug resistance genes in clinical isolates of Acinetobacter baumannii through whole genome sequencing.Molecular biology reports · 2025Article
- Antimicrobial resistance and virulence factors analysis of a multidrug-resistant Acinetobacter baumannii isolated from chickens using whole-genome sequencing.BMC microbiology · 2024Article
- Phenotypic and Genotypic Analysis of Bacterial Pathogens Recovered from Patients Diagnosed with Fever of Unknown Origin in Egypt.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Formulating co-loaded nanoliposomes with gallic acid and quercetin for enhanced cancer therapy.Heliyon · 2023Article
- Epidemiology and antimicrobial resistance trends ofFrontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection by multidrug-resistant (MDR) Acinetobacter baumannii is one of the major causes of hospital-acquired infections worldwide. The ability of A. baumannii to survive in adverse conditions as well as its extensive antimicrobial resistance make it one of the most difficult to treat pathogens associated with high mortality rates. The aim of this study was to investigate MDR A. baumannii that has spread among pediatric cancer patients in the Children's Cancer Hospital Egypt 57357. Whole-genome sequencing was used to characterize 31 MDR A. baumannii clinical isolates. Phenotypically, the isolates were MDR, with four isolates showing resistance to the last-resort antibiotic colistin. Multilocus sequence typing showed the presence of eight clonal groups, two of which were previously reported to cause outbreaks in Egypt, and one novel sequence type (ST), Oxf-ST2246. Identification of the circulating plasmids showed the presence of two plasmid lineages in the isolates, strongly governed by sequence type. A large number of antimicrobial genes with a range of resistance mechanisms were detected in the isolates, including β-lactamases and antibiotic efflux pumps. Analysis of insertion sequences (ISs) revealed the presence of IS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.